{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:29:23Z","timestamp":1793852963659,"version":"4.6.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"48","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1016\/j.vaccine.2007.09.043","type":"journal-article","created":{"date-parts":[[2007,10,9]],"date-time":"2007-10-09T12:32:14Z","timestamp":1191933134000},"page":"8140-8145","source":"Crossref","is-referenced-by-count":13,"title":["Immunogenicity and safety of a new Vero cell rabies vaccine produced using serum-free medium"],"prefix":"10.1016","volume":"25","author":[{"given":"Wagner A.","family":"Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo S.","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera Lucia","family":"Bolzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea de C\u00e1ssia R.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciane Maria M.","family":"Caporale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana B.","family":"Chaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel W.","family":"Oselka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulce A.","family":"Junqueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosana I.","family":"Panach\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo A.","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neide Y.","family":"Takaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2007.09.043_bib1","unstructured":"WHO expert consultation on rabies: first report. WHO Technical Report Series, No. 931. Geneva: World Health Organization; 2004."},{"key":"10.1016\/j.vaccine.2007.09.043_bib2","series-title":"Vaccines","first-page":"743","article-title":"Rabies vaccine","author":"Plotkin","year":"1999"},{"key":"10.1016\/j.vaccine.2007.09.043_bib3","unstructured":"WHO Expert Committee on Rabies. Eight report. WHO Technical Report Series, No. 824. Geneva: World Health Organization; 1992."},{"key":"10.1016\/j.vaccine.2007.09.043_bib4","series-title":"Laboratory techniques in rabies","first-page":"285","article-title":"Purified Vero cell vaccine for humans","author":"Montagnon","year":"1996"},{"key":"10.1016\/j.vaccine.2007.09.043_bib5","first-page":"157","article-title":"The development, benefits and disadvantages of serum-free media","volume":"99","author":"Froud","year":"1999","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2007.09.043_bib6","first-page":"233","article-title":"Development of serum-free media for cell growth and production of viruses\/viral vaccines\u2014safety issues of animal products used in serum-free media","volume":"111","author":"Merten","year":"2002","journal-title":"Dev Biol"},{"key":"10.1016\/j.vaccine.2007.09.043_bib7","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1016\/j.vaccine.2007.02.075","article-title":"Safety review of the purified chick embryo cell rabies vaccine: data from the Vaccine Adverse Event Reporting System (VAERS), 1997\u20132005","volume":"25","author":"Dobardzic","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.09.043_bib8","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.vaccine.2004.06.014","article-title":"Vero-cell rabies vaccine produced using serum-free m\u00e9dium","volume":"23","author":"Frazatti-Galinna","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.09.043_bib9","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Funda\u00e7\u00e3o Nacional de Sa\u00fade. Centro Nacional de Epidemiologia. Coordena\u00e7\u00e3o de Controle de Zoonoses e Animais Pe\u00e7onhentos. Programa Nacional de Profilaxia da raiva. Normas T\u00e9cnicas de Tratamento Profil\u00e1tico Anti-R\u00e1bico Humano. Bras\u00edlia; 2002. http:\/\/saude.pr.gov.br\/ftp\/Saudeambiental\/NORMA_TECNICA_DA_RAIVA_%202002.doc."},{"key":"10.1016\/j.vaccine.2007.09.043_bib10","series-title":"Laboratory techniques in rabies","first-page":"181","article-title":"Rapid fluorescent focus inhibition test for determining rabies virus-neutralizing antibody","author":"Smith","year":"1996"},{"issue":"8499","key":"10.1016\/j.vaccine.2007.09.043_bib11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0140-6736(86)91946-X","article-title":"New purified Vero-cell rabies vaccine prevents rabies in patients bitten by rabid animals","volume":"2","author":"Suntharasamai","year":"1986","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2007.09.043_bib12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1017\/S0022172400066286","article-title":"Purified Vero cell rabies vaccine and human diploid cell strain vaccine: comparison of neutralizing antibody responses to post-exposure regimens","volume":"96","author":"Suntharasamai","year":"1986","journal-title":"J Hyg (Lond)"},{"issue":"1","key":"10.1016\/j.vaccine.2007.09.043_bib13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0264-410X(88)90012-6","article-title":"Effectiveness and tolerance of pre- and postexposure treatment with purified inactivated rabies vaccine prepared on Vero cell line","volume":"6","author":"Klietmann","year":"1988","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2007.09.043_bib14","first-page":"23","article-title":"Five-year longitudinal study of efficacy and safety of purified Vero cell rabies vaccine for post-exposure prophylaxis of rabies in Indian population","volume":"29","author":"Seghal","year":"1997","journal-title":"J Commun Dis"},{"key":"10.1016\/j.vaccine.2007.09.043_bib15","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/S0264-410X(97)00143-6","article-title":"An immunogenicity and efficacy study of purified chick embryo cell culture rabies vaccine manufactured in Japan","volume":"15","author":"Benjavongkulchai","year":"1997","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.vaccine.2007.09.043_bib16","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0264-410X(98)00045-0","article-title":"Safety and efficacy of purified Vero cell rabies vaccine given intramuscularly and intradermally. (Results of a prospective randomized trial)","volume":"16","author":"Jaiiaroensup","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.09.043_bib17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0001-706X(99)00092-3","article-title":"Immunogenicity and effectiveness of post-exposure rabies prophylaxis with a new chromatographically purified Vero-cell rabies vaccine (CPVR): a two-stage randomized clinical trial in the Philippines","volume":"75","author":"Quiambao","year":"2000","journal-title":"Acta Trop"},{"key":"10.1016\/j.vaccine.2007.09.043_bib18","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1016\/S0264-410X(01)00238-9","article-title":"Immunogenicity, safety and lot consistency in adults of a chromatographically purified Vero-cell rabies vaccine: a randomized, double-blind trial with human diploid cell rabies vaccine","volume":"19","author":"Jones","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.09.043_bib19","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.vaccine.2004.08.001","article-title":"An immunogenicity study of a newly introduced purified Vero cell rabies vaccine (Abhayrab) manufactured in India","volume":"23","author":"Sampath","year":"2005","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2007.09.043_bib20","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1086\/427700","article-title":"Immunogenicity of purified vero cell rabies vaccine used in the treatment of fox-bite victims in India","volume":"40","author":"Matha","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2007.09.043_bib21","first-page":"693","article-title":"Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine","volume":"78","author":"Briggs","year":"2000","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2007.09.043_bib22","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1086\/515267","article-title":"Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10 years follow-up and proposal for a new booster policy","volume":"177","author":"Strady","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2007.09.043_bib23","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1016\/S0264-410X(00)00054-2","article-title":"Predictive factors for the neutralizing antibody response following pre-exposure rabies immunization: validation of a new booster dose strategy","volume":"18","author":"Strady","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.09.043_bib24","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1023\/B:JOCI.0000010429.36461.6b","article-title":"Vaccination with rabies to study the humoral and cellular immune response to a T-cell dependent neoantigen in man","volume":"23","author":"Brinkman","year":"2003","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.vaccine.2007.09.043_bib25","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1056\/NEJMoa051568","article-title":"An antibody-deficiency syndrome due to mutations in the CD19 gene","volume":"354","author":"van Zelm","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2007.09.043_bib26","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/(SICI)1096-9071(199612)50:4<283::AID-JMV1>3.0.CO;2-4","article-title":"Nonresponse to hepatitis B vaccines and kinetics of anti-HBs production","volume":"50","author":"Zuckerman","year":"1996","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2007.09.043_bib27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/jmv.20524","article-title":"Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines","volume":"78","author":"Zuckerman","year":"2006","journal-title":"J Med Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07010717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07010717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T15:52:19Z","timestamp":1546530739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X07010717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":27,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["S0264410X07010717"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2007.09.043","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}